MedTrace Logo

Mini-Mental State (MMS-LS) and Sign Language

NCT02005679 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2019-02-15

No results posted yet for this study

Summary

In France the prevalence of pre-lingual deafness is between 1 and 1.4 per 1000 habitants, and according to very conservative estimates, about 44 000 deaf persons use the sign language. Additionally, the prevalence of dementia in France is close to 1% (850 000 dements for a total population of 65 millions). The prevalence of dementia in pre-lingual deaf adults has also been described and is between 1 and 1.4 /100 000 habitants.

The Mini Mental State Examination (MMSE) of Folstein is a test recommended to perform the cognitive evaluation for the detection of mental disorders including dementia, and a consensual French version exists prepared by GRECO (Group of Research and Cognitive Assessments). However, to date, there are no simple, rapid and validated screening tests to study cognitive disorders in deaf persons who use the sign language. The only tests available allow a late diagnosis avoiding an optimal treatment of the patients.

Conditions

  • Prelingual Deafness
  • Retention Disorders, Cognitive

Interventions

BEHAVIORAL

application of the mini-mental state test

Sponsors & Collaborators

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Benoît Drion, MD · Groupement des Hôpitaux de l'Institut Catholique de Lille, Unité d'Accueil et de Soins des Sourds en Langue des Signes et Réseau Sourds et Santé

  • Amélie Lansiaux, MD · Groupement des Hôpitaux de l'Institut Catholique de Lille, Medical Research Department

  • Isabelle Ridoux, MD · CHU de Rennes, Hôpital de Pontchaillou

  • Corine Gilda Scemama-Ammar, MD · Hôpital de la Conception, Pôle psychiatrie, Marseille

  • Charlotte Crinquette, MD · Groupement des Hôpitaux de l'Institut Catholique de Lille

  • Isabelle Bouillevaux, MD · CHRU de Nancy, Unité Régionale d'Accueil et de Soins pour Sourds et malentendants

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-17
Primary Completion
2017-12-07
Completion
2017-12-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005679 on ClinicalTrials.gov